Navigation Links
NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development
Date:3/31/2011

al gains that will allow the pharmaceutical industry to complete higher quality cardiac safety analysis faster, more reliably, and at significantly lower cost."Conference InformationCardiovascular Safety in Drug Development: State-of-the-Art AssessmentsCo-sponsored by FDA, Cardiac Safety Research Consortium, and Heart Rhythm SocietyDate(s) And Time(s): Apr 13 2011 8:00AM - Apr 15 2011 1:00PMLocation: L'Enfant Plaza Hotel 480 L'Enfant Plaza Southwest Washington, DC 20024-0478 About QTinno TechnologyNewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.

About the Cardiac Safety Research ConsortiumThe Cardiac Safety Research Consortium (CSRC) was launched in 2006 under the FDA Critical Path Initiative with the mission of advancing scientific knowledge on cardiac safety for new and existing medical products.  CSRC supports research by engaging stakeholders from industry, academia, and government to share data and expertise. Key objectives include facilitating focused pragmatic research that will inform regulatory processes with regard to cardiac safety, and to develop knowledge and strategies intended to improve the evaluative sciences in relation to cardiac safety and product development.  For more information, visit www.cardiac-safety.org.

About
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NewCardio Announces Positive Results From Third Clinical Validation Study
2. Vincent W. Renz Joins NewCardio as President
3. NewCardio Leadership to Present Two Abstracts at ISCE Conference
4. NewCardio Announces Master Services Agreement With Dedicated Phase I
5. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio CEO Increases Equity Position
8. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
9. NewCardio Announces Financial Results for Its 2010 Third Quarter
10. NewCardios Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
11. NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver Disease Global ... Fatty Liver Disease clinical trial scenario. This report provides ... trials on Fatty Liver Disease . It includes an ... as per the site of trial conduction across the ... clinical trials by their phase, trial status, prominence of ...
(Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014  As ... is pleased to announce the addition of new ... Center. The Medical Devices Knowledge Center ... research in the healthcare industry. Users have access ... expert, Kalorama Information, published from 1998 to present ...
Breaking Medicine Technology:Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3
... RDEA594 Data to Be Presented at the 2008 Annual European Congress of, Rheumatology ... Phase 1 Human Study of RDEA594 Planned in Second Half of ... ... Biosciences, Inc.,(Nasdaq: RDEA ) today announced the identification of its lead development,candidate ...
... filing anticipated in 1Q 2009 -, PRINCETON, ... ) has nominated PSI-7851 as a lead development ... (HCV). PSI-7851 is a proprietary,nucleotide analogue polymerase inhibitor ... Practice (GLP) animal toxicity studies required for,submission of ...
Cached Medicine Technology:Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3
(Date:8/27/2014)... 27, 2014 When a friend invited Misty Mozejko ... But it was the beginning of a new way of life ... unhappy,” says Misty. “I knew I needed to turn my life ... may have been, Misty stuck with the program. “It was so ... so out of my comfort zone, but between the boot camp ...
(Date:8/27/2014)... 2014 Hastings and Hastings, a firm ... local offices is pleased to report having saved a ... $150,000. Hastings and Hastings is a dedicated and focused ... everything from automobile accident cases to pedestrian cases and ... routinely works with slip and fall accident victims, motorcycle ...
(Date:8/27/2014)... Minneapolis, Minn. (PRWEB) August 27, 2014 ... law and policy will gather at the Minneapolis Marriott ... into the worldwide explosion of robotics and autonomous systems ... , In recognition of the wide variety of ... Alley Conference & Expo created nine different tracks of ...
(Date:8/27/2014)... StartX , a nonprofit technology accelerator ... a pioneering institute driving biotechnology innovation at the University ... laboratory customized for the needs of early stage medical ... lab space, named “StartX-QB3 Labs,” is the first research ... Care focused on developing entrepreneurs from academia to industry. ...
(Date:8/27/2014)... For the first time, a living ... surgery when triple-board certified, Park Avenue plastic surgeon Dr. ... he has created from life – and the faces ... a unique event on September 9, 2014 at prestigious ... Street. The “faces” who will be appearing in this ...
Breaking Medicine News(10 mins):Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $6,500 On A Settlement Of $150,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $6,500 On A Settlement Of $150,000 3Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 2Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 3Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 4Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 5Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 2Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 3Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 4Health News:Presenting A Remarkable Fusion of Art, Fashion and Plastic Surgery 2
... ... strength and momentum in the business services sector. , ... Baltimore, Md. (PRWEB) November 24, 2009 -- Slate ... New Markets Venture Partners ( www.newmarketsvp.com ), a venture capital firm based in College ...
... Two ... - ban,- don: verb: to leave completely and finally; forsake utterly; to desert. ... Vancouver, Canada ... the second webinar is its groundbreaking "The New Paradigm for 21st Century Therapy" series ...
... ... impacted by acute sinusitis or chronic sinusitis, Sinus Dynamics non-invasive nasal ... types of Sinusitis without any limitation or interference associated with any ... nasal nebulized antibiotics with mean particle diameter of 3.2 µm had ...
... ... EyeCentral Remote Video Platform for the Security Industry to Generate Recurring Monthly Revenue for ... ... Remote Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central ...
... WASHINGTON, Nov. 24 New peer-reviewed data finding that fewer ... chronic hepatitis C virus have received anti-viral therapy in recent ... move urgently on bipartisan legislation to support new state-based detection, ... (NVHR) said today. , The NVHR warns ...
... Researchers from the University of Michigan determined that only ... C virus (HCV) infection received antiviral therapy between 2002 ... in part because only half of the patients know ... by 2030 less than 15% of liver-related deaths from ...
Cached Medicine News:Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 2Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 3Health News:Home For the Holidays: MyShrink.com Announces the Second in its Successful Six-Part Webinar Series: "Abandonment: The Hidden Fear" 2Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 2Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 4Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 3Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2
... Sunrise Technologies has developed laser thermal keratoplasty (LTK). ... 30, 2000 for the temporary reduction of hyperopia ... years and older with up to 0.75 diopters ... 6 months. Unlike most refractive surgery, LTK ...
... The OcuLight family of infrared laser ... SLx models. These diode lasers serve as ... devices and applications, require no regular maintenance ... with their compact design. The OcuLight SLx ...
... Danker Laboratories manufacturers ... RGP orthokeratology lenses (also ... or "Corneal Reshaping" Lenses) ... specifications and demanding standards ...
... contact lenses used for corneal refractive therapy, ... The patient wears the lenses overnight while ... the day, nearsightedness is corrected or greatly ... contact lenses apply slight pressure to the ...
Medicine Products: